According to the Zhitong Finance App, Quanxin Bio-B (02509.HK) announced that on November 5, 2026, the company and Caldera Therapeutics, Inc. entered into an external licensing agreement for a pre-clinical bispecific antibody project targeting TL1a and IL-17 (specifically IL-17A and IL-17A/F).

Zhitongcaijing · 4d ago
According to the Zhitong Finance App, Quanxin Bio-B (02509.HK) announced that on November 5, 2026, the company and Caldera Therapeutics, Inc. entered into an external licensing agreement for a pre-clinical bispecific antibody project targeting TL1a and IL-17 (specifically IL-17A and IL-17A/F).